November 14, 2026 — Tcelltech today presented the phase 1 results of TX103 at the 2026 Society for Neuro-Oncology (SNO) Annual Meeting. TX103 is an investigational autologous CAR-T cell therapy that targets B7-H3 and is delivered intracranially to patients with recurrent glioblastoma. The results were recently published in Nature Medicine.
In the open-label, 3+3 dose-escalation study (NCT05241392), 15 patients with B7-H3-positive recurrent glioblastoma received a total of 72 intracranial infusions across three dose levels. The primary endpoints were safety, the maximum tolerated dose and the recommended phase 2 dose.
Key findings
- Safety: There were no dose-limiting toxicities and no treatment-related deaths, and a maximum tolerated dose was not reached. Most treatment-related adverse events were grade 1 or 2, and all cytokine release events were grade 1. Five grade 3 events occurred, three of which were serious (raised intracranial pressure, epilepsy and depressed consciousness). All were clinically managed. Neurologic toxicity requires active monitoring.
- Dose: Neurologic events were more frequent and more severe at the highest dose level. The middle dose level, 6 × 10⁷ cells per infusion, was therefore selected as the recommended phase 2 dose.
- Activity (preliminary): Disease control was achieved in 8 of 14 patients with measurable disease (57.1%), including one complete response sustained through the latest follow-up.
- Survival (exploratory): The 12-month overall survival rate was 66.7%, and median overall survival was 19.1 months from first infusion. Median progression-free survival was 1.87 months.
- Biology: CAR-T cells expanded markedly and cytokines were induced in cerebrospinal fluid. Peripheral exposure was limited, and there was no accumulation with repeated infusions.
Interpreting the results
These results must be interpreted with caution. This was a small, early-phase, single-center study designed to assess safety and select a dose, not to establish efficacy. Bevacizumab was used in some patients, which may have influenced the outcomes observed.
Next steps
Tcelltech is committed to continuing the development of TX103. The company plans to conduct further clinical studies, including a phase 2 evaluation at the recommended dose of 6 × 10⁷ cells per infusion.
Acknowledgments
Tcelltech thanks the patients who took part in the study and their families. The company also thanks its clinical and manufacturing teams, including its collaborators at Beijing Tiantan Hospital.
Publication
Zhang Y, Chi X, Feng R, et al. Intracranial delivery of B7-H3-targeting CAR-T cells for recurrent glioblastoma: a phase 1 trial. Nature Medicine. 2026;32(9):3268-3275. Read the paper: https://www.nature.com/articles/s41591-026-04557-6
About TX103
TX103 is an investigational autologous chimeric antigen receptor T (CAR-T) cell therapy that targets B7-H3. It is delivered intracranially and is being developed for recurrent glioblastoma. TX103 has not been approved by any regulatory authority.